After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma ...

Novocure's Tumor Treating Fields tech offers promise in oncology. NVCR trades at a compelling valuation after the recent ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

It is notable that a majority of patients in this analysis (n = 44, 88.0%) received previous temozolomide; this is despite the predominance of unmethylated MGMT promoter in H3 K27M–mutant glioma, lack ...